GILD Stock Recent News
GILD LATEST HEADLINES
Gilead stock is nearing a breakout after the company reported better-than-expected second-quarter sales and profit.
Gilead Sciences on Thursday reported second-quarter profit that handily beat Wall Street estimates, driven by lower operating expenses and higher product sales, and the drugmaker raised its outlook for full-year earnings.
After a disastrous performance in the first half of 2024, Gilead Sciences stock has rebounded strongly since mid-June. With Gilead Sciences due to report its Q2 results on Thursday, it's a good time to assess what we can expect and whether the rebound was justified. I will specifically discuss Gilead's novel GLP-1 receptor agonist, GS-4571, and other news that has emerged recently.
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
While Gilead (GILD) has been under pressure year to date due to pipeline setbacks, holding on to this biotech giant should be prudent at current levels.
Gilead Sciences (GILD) closed the most recent trading day at $76.49, moving +0.57% from the previous trading session.
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Gilead Sciences has dropped 15% YTD, impacted by disappointing trial results from Trodelvy after acquiring Immunomedics for over $20 billion. Despite challenges, the company had a financially strong 1Q 2024, with growth in non-Veklury product sales and a strong HIV business. Gilead Sciences has an impressive R&D arm and strong financial performance, with a focus on building a balanced portfolio for long-term shareholder returns.